price of good health care.

The author examines the outlook for biologics in managing inflammatory conditions in the midst of financial pressures on the healthcare system. Topics discussed include increased spending on biologics as the number of targeted therapies approved for inflammatory diseases continue to increase and its implications to the financial pressure on the health care system. Also mentioned is the cost effectiveness of biologics despite its high cost.